Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$51.32 USD

51.32
666,097

-1.53 (-2.90%)

Updated Nov 6, 2024 10:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).

    Horizon Pharma Gets Health Canada Approval for Procysbi

    Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

      Arpita Dutt headshot

      4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio

      The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.

        Sanofi: Should Value Investors Consider SNY Stock?

        Value investing is easily one of the most popular ways to find great stocks in any market environment.

          Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

          Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

            Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

            Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

              Seres Therapeutics' Stock Up as SER-109 Moves to Phase III

              Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.

                Intercept (ICPT) Releases Data from Phase II Flint Trial

                Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

                  Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M

                  Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.

                    Ryan McQueeney headshot

                    3 Large Cap Pharma Stocks to Buy Now

                    Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!

                      Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

                      Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

                        Is the Options Market Predicting a Spike in Sanofi (SNY) Stock?

                        Investors in Sanofi (SNY) need to pay close attention to the stock based on moves in the options market lately.

                          Amgen Files for Repatha in the U.S., EU for Expanded Use

                          Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

                            Sanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions

                            One stock that might be an intriguing choice for investors right now is Sanofi (SNY).

                              Regeneron Announces Positive Data on Carcinoma Candidate

                              Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

                                Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

                                Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

                                  Arpita Dutt headshot

                                  5 Drug Stocks in Focus on World MS Day

                                  Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                                    Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

                                    We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

                                      Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                                      After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

                                        Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

                                          Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

                                          We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

                                            Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                                            Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                                              Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

                                              Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

                                                Arpita Dutt headshot

                                                Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?

                                                Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

                                                  This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.